Early Diagnosis and Management of SSc-ILD

What Is SSc-ILD?

SSc-ILD Is a Shared Disease for Rheumatologists and Pulmonologists

Diagnosing ILD in Patients With SSc

ILD Is the Leading Cause of Death Related to SSc

How Should Pulmonologists and Rheumatologists Approach SSc-ILD?

Epidemiology of SSc in Patients With ILD

Diagnosis of SSc-ILD

High Resolution CT Imaging

A Simple Staging System to Predict Prognosis

Diagnosis of SSc-ILD: Summary

Management of SSc-ILD

Scleroderma Lung Study I Oral Cyclophosphamide vs Placebo

Tolerability of Oral Cyclophosphamide

Scleroderma Lung Study II Mycophenolate Mofetil vs Oral Cyclophosphamide

Combination Prednisone and Mycophenolate Mofetil

Current Approach to Treatment of SSc-ILD

Potential Future Approaches to Treatment of SSc-ILD?

LOTUSS Trial Pirfenidone

Scleroderma Lung Study III Pirfenidone With Mycophenolate Mofetil

SENSCIS Trial Nintedanib

SENSCIS Trial Key Eligibility Criteria

SENSCIS and IMPULSIS Trials Annual Rate of Decline in FVC

SENSCIS Trial Secondary Endpoints

SENSCIS Trial Tolerability -- Most Frequent Adverse Events

Treatment Strategies: Summary

Evaluating Treatment Response

Collaboration With Multidisciplinary Care

Abbreviations